Ｍasaki Ｋato（Kinki/Osaka）
Professor and Chair, Director of Clinical Department
In our brain screening program, we utilize brain MRI, amyloid PET, and higher-order cognitive function tests to detect dementia before clinical onset.
We provide highly specialized expertise and a comprehensive follow-up system for the diagnosis and treatment of treatment-resistant depression.
Our team possesses advanced skills and expertise to accurately diagnose and effectively manage difficult-to-treat psychiatric disorders, guiding patients toward recovery.
- Clinical department/Main areas of expertise
- Specialized area
-
- Diagnosis and Treatment of Treatment-Resistant Depression
Clinical Pharmacology: Appropriate Use of Psychotropic Medications and Monotherapy Detail
- Diagnosis and Treatment of Treatment-Resistant Depression
- Qualifications/Academia/Position
-
- Doctor of Medical Science (Ph.D. in Medicine)
- Designated Psychiatrist under the Mental Health and Welfare Act (Japan)
- Board-Certified Psychiatrist / Clinical Instructor
- Supervising / Board-Certified Physician, Japanese Society of Clinical Neuropsychopharmacology
- Board-Certified / Supervising Psychiatrist in General Hospital Collaboration
- Certified Occupational Health Physician, Japan Medical Association
- Councilor, Japanese Society of Psychiatry and Neurology
- Councilor, Japanese Association of General Hospital Psychiatry
- Councilor, Japanese Society of Mood Disorders
- Director, Japanese Society of Neuropsychopharmacology
- Director, Japanese Society of Clinical Neuropsychopharmacology
- Affiliated hospital
- Kansai Medical University Medical Center
- Website
- https://hp.kmu.ac.jp/takii/
- location
-
〒570-8507
10-15 Fumizono-cho, City of Moriguchi, Google Map Map
- Biography
-
- 1997
- Graduated from Kansai Medical University
- 1997
- Joined the Department of Psychiatry and Neurology, Kansai Medical University
- 2000
- Okura-kai Medical Corporation, Geisei Hospital
- 2002
- Assistant Professor, Kansai Medical University
- 2006
- Department of Psychiatry and Neurology, University of Bologna
- 2008
- Assistant Professor, Kansai Medical University
- 2009
- Associate Professor, Kansai Medical University
- 2014
- Associate Professor, Kansai Medical University
- 2019
- Chair, Department of Psychiatry and Neurology, Kansai Medical University Hospital
- 2024
- Professor, Kansai Medical University
- paper
-
- Antidepressants available in Japan for older people with major depressive disorder: A systematic review and meta-analysis. Neuropsychopharmacol Rep. 2024;44:267-271.
- Characteristics of persistent depression in the long-term: Randomized controlled trial and two-year observational study. Heliyon. 2023;9:e20917.
- "Adjunctive brexpiprazole 1 mg and 2 mg daily for Japanese patients with major depressive disorder following inadequate response to antidepressants: a phase 2/3, randomized, double-blind (BLESS) study. " Psychiatry Clin Neurosci. 2023.
- "Efficacy and safety of zuranolone in Japanese adults with major depressive disorder: A double-blind, randomized, placebo-controlled, phase 2 clinical trial." Psychiatry Clin Neurosci. 2023.
- "The efficacy and safety of lurasidone in bipolar I depression with and without rapid cycling: A pooled post-hoc analysis of two randomized, placebo-controlled trials." J Affect Disord. 2023.
- Appropriate duration of antidepressant medications for prevention of depressive relapse and the impact of life stage. Mol Psychiatry. 2023.
- Usefulness of mirtazapine and SSRIs in late-life depression: post hoc analysis of the GUNDAM study. Eur J Clin Pharmacol. 2023.
- "Changes in Multiple microRNA Levels with Antidepressant Treatment Are Associated with Remission and Interact with Key Pathways: A Comprehensive microRNA Analysis. " International Journal of Molecular Sciences. 2023;24:12199.
- Personality as a basis for antidepressant selection for patients with depression: A two-point outcome study at 4 and 8 weeks. J Affect Disord. 2022;314:27-33.
- "Multiple Pre-Treatment miRNAs Levels in Untreated Major Depressive Disorder Patients Predict Early Response to Antidepressants and Interact with Key Pathways." Journal of Molecular Sciences. 2022;23:3873.
- "Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis." Mol Psychiatry. 2021;26:118-133.
- Medical Education Panel of the Japanese Society of Clinical N. Pharmacological management of depression: Japanese expert consensus. J Affect Disord. 2020;266:626-632.
- Medical Education Panel of the Japanese Society of Clinical N. Pharmacological management of bipolar disorder: Japanese expert consensus. Bipolar Disord. 2020.
- Non response at week 4 as clinically useful indicator for antidepressant combination in major depressive disorder. A sequential RCT. J Psychiatr Res. 2017;89:97-104.
- book
-
- Clinical Practice Guideline for Depression (Provisional Title), Japanese Society of Mood Disorders Publisher: Igaku-Shoin (planned) Publication date: 2025 (TBD) Masaki Kato – Executive Director (Responsible Officer)
- Practice Guidelines for Bipolar Disorder by the JSMD (Japanese Society of Mood Disorders). 633-645. Psychiatry Clin Neurosci. 2024;78 Kato T, Ogasawara K, Motomura K, Kato M, et al
- Chapter 2. Manic Episode Clinical Practice Guideline for Bipolar Disorder (Bipolar Disorder 2023), Japanese Society of Mood Disorders Igaku-Shoin, 2023; Vol. 1, No. 1, pp. 31–59. Authors: Masaki Kato, Iga, Tajika, Hori, Ogata, Koshikawa
- Bipolar Disorder: Depressive State; Current Therapeutic Guidelines – This Is How I Treat (2023 Edition) Igaku-Shoin, 2023; pp. 1043–1044. Author: Masaki Kato
- Chapter 2. Bipolar Disorder: What Is and Is Not Evidence-Based — Bipolar Disorder: What You Wanted to Know! Expert Consensus on Psychopharmacotherapy Shinko Igaku Shuppansha, 2023; Vol. 1, pp. 112–128. Author: Masaki Kato [et al.]
- Pharmacotherapy: Section 1. Antidepressants. Textbook of Clinical Neuropsychopharmacology for Specialists Edited by the Board of Specialists, Japanese Society of Clinical Neuropsychopharmacology Seiwa Shoten, 2022. Author: Masaki Kato
- Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of Schizophrenia" :266-324 Neuropsychopharmacol Rep 2021 Sep;41(3) 2021年 Ishigooka J, Iwata N, Kusumi I,et al
- Chapter 5. Appropriate Use of Basic Psychotropic and Neurological Medications: How to Choose SSRI, SNRI, NaSSA, or SRIM for Depression? Monthly YAKUJI, May Special Issue, Vol. 63, No. 7, 2021; pp. 224–232. Jiho, Inc. Author: Masaki Kato
This doctor's treatment program
-
Brain Screening Program 【Kansai Medical University General Medical Center】
Medical checkupDepartment of NeuropsychiatryKansai Medical University Medical Center（Kinki/Osaka）
In our brain screening program, we utilize brain MRI, amyloid PET, and neuropsychological testing to detect dementia at a preclinical stage. We also perform screening and diagnosis for other conditions such as depression and insomnia, in addition to dementia.
With advanced diagnostic modalities such as amyloid PET, cerebral blood flow studies, brain MRI, comprehensive polysomnography, electroencephalography (EEG), neuropsychological testing, and blood tests, our center is staffed with numerous specialists certified by the Japanese Society of Psychiatry and Neurology, as well as the Japanese Society of Clinical Neuropsychopharmacology, along with experts in dementia and depression. This enables us to provide accurate diagnosis, appropriate treatment strategies, and second opinions when necessary.
See details